NovaBay Pharmaceuticals: Funding, Investors & Team (Oct 2026)
Going Beyond Antibiotics® Developing Anti-Infective Compounds Effective Against Bacteria, Viruses and Fungi. NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company developing products for the eye care market. We are currently focused primarily on commercializing prescription Avenova® for managing hygiene of the eyelids and lashes in the United States. Avenova is the only eye care product formulated with a proprietary, stable and pure form of hypochlorous acid called Neutrox®. By replicating the anti-microbial chemicals used by white blood cells to fight infection, Neutrox has proven in laboratory testing to have broad antimicrobial properties. Avenova with Neutrox removes debris from the skin on eyelids and lashes without burning or stinging. We have developed additional commercial products containing Neutrox, including our NeutroPhase® Skin and Wound Cleanser for wound care and CelleRx® for the dermatology market. We have partnerships for NeutroPhase in the U.S. as well as select overseas markets, most notably China. In addition to our Neutrox family of products, we have also synthesized and developed a second category of novel compounds aimed at harnessing the power of white blood cell chemistry to address the global, topical anti-infective market. This second product category includes auriclosene, our lead clinical-stage Aganocide® compound, which is a patented, synthetic molecule with a broad spectrum of activity against bacteria, viruses and fungi.
NovaBay Pharmaceuticals has raised $5.3M across 1 funding round on record, the most recent a Post-IPO Equity of $5.3M announced in Sep 2022.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
NovaBay Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Sep 2022.
NovaBay Pharmaceuticals Funding Rounds
NovaBay Pharmaceuticals Founders and Leadership Team
Contact details for the NovaBay Pharmaceuticals team: 1 of 1 has an email address on file.
Start 14-day free trial →NovaBay Pharmaceuticals Funding Compared to Other Biotechnology Startups
NovaBay Pharmaceuticals' latest round of $5.3M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like NovaBay Pharmaceuticals in Biotechnology and Emeryville
Companies Similar to NovaBay Pharmaceuticals
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
NovaBay Pharmaceuticals Funding FAQs
What does NovaBay Pharmaceuticals do?
Going Beyond Antibiotics® Developing Anti-Infective Compounds Effective Against Bacteria, Viruses and Fungi. NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company developing products for the eye care market. We are currently focused primarily on commercializing prescription Avenova® for managing hygiene of the eyelids and lashes in the United States. Avenova is the only eye care product formulated with a proprietary, stable and pure form of hypochlorous acid called Neutrox®. By replicating the anti-microbial chemicals used by white blood cells to fight infection, Neutrox has proven in laboratory testing to have broad antimicrobial properties. Avenova with Neutrox removes debris from the skin on eyelids and lashes without burning or stinging. We have developed additional commercial products containing Neutrox, including our NeutroPhase® Skin and Wound Cleanser for wound care and CelleRx® for the dermatology market. We have partnerships for NeutroPhase in the U.S. as well as select overseas markets, most notably China. In addition to our Neutrox family of products, we have also synthesized and developed a second category of novel compounds aimed at harnessing the power of white blood cell chemistry to address the global, topical anti-infective market. This second product category includes auriclosene, our lead clinical-stage Aganocide® compound, which is a patented, synthetic molecule with a broad spectrum of activity against bacteria, viruses and fungi.
How much funding has NovaBay Pharmaceuticals raised?
NovaBay Pharmaceuticals has raised $5.3M across 1 round on record. The most recent is a Post-IPO Equity of $5.3M announced in Sep 2022.
When did NovaBay Pharmaceuticals last raise funding?
NovaBay Pharmaceuticals' most recent funding round on record is a Post-IPO Equity of $5.3M, announced in Sep 2022.
Who is the CEO of NovaBay Pharmaceuticals?
Mark Sieczkarek is listed as CEO at NovaBay Pharmaceuticals.
Where is NovaBay Pharmaceuticals headquartered?
NovaBay Pharmaceuticals is based in Emeryville, California, United States.
How many employees does NovaBay Pharmaceuticals have?
NovaBay Pharmaceuticals is in the 101-250 employee band.
How does NovaBay Pharmaceuticals' funding compare to other Biotechnology startups?
NovaBay Pharmaceuticals' latest round of $5.3M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's NovaBay Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for NovaBay Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.